The phosphatidylinositol (PI) 3-kinase/Akt signaling pathway has a prominent role in cell survival and proliferation, in part, by regulating gene expression at the transcriptional level. Previous work using global expression profiling identified FOXOs and the E-box-binding transcription factors MITF and USF1 as key targets of PI 3-kinase signaling that lead to the induction of proapoptotic and cell cycle arrest genes in response to inhibition of PI 3-kinase. In this study, we investigated the role of p53 downstream of PI 3-kinase signaling by analyzing the effects of inhibition of PI 3-kinase in Rat-1 cells, which have wild-type p53, compared with Rat-1 cells expressing a dominant-negative p53 mutant. Expression of dominant-negative p53 conferred partial resistance to apoptosis induced by inhibition of PI 3-kinase. Global gene expression profiling combined with computational and experimental analysis of transcription factor binding sites demonstrated that p53, along with FOXO, MITF and USF1, contributed to gene induction in response to PI 3-kinase inhibition. Activation of p53 was mediated by phosphorylation of the histone acetyltransferase Tip60 by glycogen synthase kinase (GSK) 3, leading to activation of p53 by acetylation. Many of the genes targeted by p53 were also targeted by FOXO and E-box-binding transcription factors, indicating that p53 functions coordinately with these factors to regulate gene expression downstream of PI 3-kinase/Akt/GSK3 signaling.
Subject Category: Cancer
The phosphatidylinositol (PI) 3-kinase/Akt signaling pathway has a central role in the growth and survival of both normal and malignant cells. 1, 2 Signaling by PI 3-kinase downstream of growth factor receptors is required to suppress apoptosis of most mammalian cell types, as well as acting to stimulate cell proliferation. Oncogenic mutations affecting the PI 3-kinase/ Akt pathway are among the most common abnormalities found in human tumors, and inhibitors of PI 3-kinase are currently being evaluated as cancer chemotherapeutic agents in clinical trials. 1, 2 Downstream targets of PI 3-kinase/Akt signaling include the protein kinases mTOR, which is a key regulator of translation and autophagy, 3, 4 and glycogen synthase kinase (GSK) 3, which is a proapoptotic protein kinase inhibited by Akt phosphorylation. 5, 6 Akt and GSK3 act to phosphorylate several direct regulators of cell survival and proliferation, including Mcl1, Bad and cyclin D. [7] [8] [9] [10] GSK3 also regulates translation via phosphorylation of eIF2B, 11, 12 and both Akt and GSK3 regulate gene expression by phosphorylating a variety of transcription factors. [13] [14] [15] In order to elucidate the program of gene expression regulated by PI 3-kinase, we have used global gene expression profiling to identify changes in gene expression that result from inhibition of PI 3-kinase in proliferating cells. 16 Early changes in gene expression, coinciding with the onset of apoptosis, included the induction of genes encoding proteins that mediate apoptosis and cell cycle arrest as well as the downregulation of genes that mediate cell survival and proliferation. Bioinformatic analysis, chromatin immunoprecipitation (ChIP) and RNA interference further allowed us to identify key transcription factors that were regulated by PI 3-kinase signaling and contributed to these changes in gene expression. Downregulation of genes in response to inhibition of PI 3-kinase resulted in part from a loss of NFkB activity, 16 as well as from increased mRNA degradation due to activation of the mRNA destabilizing proteins BRF1 and KSRP. 17 Induction of upregulated genes in response to PI 3-kinase inhibition was mediated in part by FOXO transcription factors, 18 which are well-established inhibitory targets of Akt. 19, 20 In addition, many of the genes induced following inhibition of PI 3-kinase were targeted by the E-box-binding transcription factors MITF and USF1, which were activated as a result of phosphorylation by GSK3. 18 The gene expression analyses discussed above were performed principally in T98G glioblastoma cells, which are widely used as a model for growth factor-dependent human cells. 21, 22 However, TP53 is inactivated by mutation in T98G cells, 23 so any role for p53 in the transcriptional response to PI 3-kinase inhibition would not have been detected in this cell line. The p53 tumor suppressor is a major regulator of cell proliferation and apoptosis, which is activated in response to DNA damage and is mutated in B50% of human cancers. [24] [25] [26] [27] Although PI 3-kinase signaling can affect p53 activity, [28] [29] [30] the role of p53 in the cellular response to inhibition of PI 3-kinase in cells without DNA damage has not been determined. In this study, we investigated the role of p53 in apoptosis and changes in the program of gene expression resulting from inhibition of PI 3-kinase in otherwise normally proliferating cells. We addressed this question by characterizing the transcriptional response to inhibition of PI 3-kinase in Rat-1 cells, which have a normal Tp53 gene, 31 ,32 compared with Rat-1 cells expressing a dominant-negative p53 mutant. Analysis of apoptosis and gene regulation in these cells indicates that p53 is a major component of the network that contributes to cell survival and alterations in gene expression downstream of PI 3-kinase signaling, along with FOXO, MITF and USF1. The principal mechanism leading to activation of p53 in response to inhibition of PI 3-kinase is phosphorylation of the histone acetyltransferase Tip60 by GSK3, leading to acetylation and activation of p53. Major changes in gene expression and cell survival following inhibition of PI 3-kinase thus result from the activation of p53, MITF and USF1 via GSK3, in addition to the activation of FOXOs resulting directly from inhibition of Akt.
Results
Characterization of Rat-1 cells expressing dominantnegative p53. In order to investigate the role of p53 in apoptosis and transcriptional regulation downstream of PI 3-kinase, we characterized the effects of inhibition of PI 3-kinase in Rat-1 cells, which have wild-type p53, 31, 32 compared to Rat-1 cells expressing a dominant-negative p53 mutant. Rat-1 cells were transfected with a plasmid conferring resistance to G418 and driving expression of the dominantnegative p53 mutant V143A. 6, 33 Two stably transformed clones (designated DN1 and DN2) were selected for further study, both of which expressed the transfected dominantnegative p53 at levels Bfourfold greater than endogenous p53 in Rat-1 cells (Figure 1a) . Induction of the p53 target genes Bax and Cdkn1a in response to activation of p53 by treatment with a low dose of actinomycin D 34, 35 was blocked in both clones expressing the dominant-negative mutant (Figure 1b) , indicating that p53 was effectively inhibited.
We investigated the effect of dominant-negative p53 expression on apoptosis in response to inhibition of PI 3-kinase by treating cells with the small-molecule inhibitor, PI-103. 36 Inhibition of PI-3 kinase rapidly induced apoptosis in both wild-type Rat-1 cells and cells expressing dominantnegative p53, as indicated by DNA fragmentation as early as 1 h after treating with PI-103 ( Figure 1c ). However, quantification by TUNEL assays indicated that apoptosis was significantly inhibited in both clones expressing the dominantnegative p53 mutant (Figure 1d ). These results indicate that p53 contributes to but is not essential for apoptosis in response to inhibition of PI 3-kinase. Similar results were (Figure 2 ). The upregulation of 14 of these genes was significantly inhibited in the Rat-1 clones-expressing dominant-negative p53, indicating that p53 contributed to their induction following inhibition of PI 3-kinase ( Figure 2a) . We also observed p53-dependent induction of the wellcharacterized p53 target gene Cdkn1a, which encodes p21, in response to inhibition of PI 3-kinase with either GDC-0941 or PI-103. Similar results were obtained for several representative genes in both the DN1 and DN2 cells expressing dominant-negative p53 (Figure 2b) . Four of the p53-dependent genes induced by inhibition of PI 3-kinase (Ccng2, Gadd45A, Tp53inp1 and Nupr1) have previously been identified as p53 targets. [38] [39] [40] The genes induced in response to inhibition of PI 3-kinase in Rat-1 cells included genes encoding proteins with wellcharacterized roles in cell cycle arrest and/or apoptosis (ATROGIN-1, CCNG2 and TXNIP) that were also induced by inhibition of PI 3-kinase in T98G cells. 16, 18 The role of representative p53 target genes (Atrogin-1, Gadd45A, Nupr1, Tp53inp1 and Txnip) in apoptosis induced by PI 3-kinase inhibition was tested by siRNA knockdowns (Figure 2c ). Inhibition of PI 3-kinase for 24 h resulted in 50-55% cell death ( Figure 2c ). Knockdown of four of the five p53 target genes tested (all except Nupr1) significantly reduced cell death, indicating the biological relevance of these genes in the cellular response to PI 3-kinase inhibition.
Identification of genes targeted by FOXO, MITF, USF1 and p53. The inhibition of induction of a subset of genes by expression of dominant-negative p53 indicates that inhibition of PI 3-kinase leads to activation of p53, which has a role in the transcriptional response. However, as the induction of most genes was unaffected or only partially inhibited by dominant-negative p53, it appears that p53 is only one component of the transcriptional response to PI 3-kinase inhibition. We previously reported that FOXO and the E-boxbinding transcription factors MITF and USF1 had a major role in the induction of cell cycle arrest and proapoptotic genes in response to inhibition of PI 3-kinase in the p53-deficient T98G cell line. 18 FOXO, MITF and USF1 were also activated in Rat-1 cells in response to PI 3-kinase inhibition, 18 suggesting that these factors as well as p53 contribute to gene induction.
To further characterize the roles of FOXO, MITF, USF1 and p53 in the transcriptional program activated by PI-3 kinase inhibition, we identified transcription factor-binding sites that were overrepresented in the upstream regions of the genes induced by PI 3-kinase inhibition in Rat-1 cells. Computational analysis, as previously described, 16, 41 was used to identify predicted binding sites that were conserved in human and rat sequences and were statistically overrepresented in the genes induced by inhibition of PI 3-kinase. Eighteen of the 26 induced genes were used for this analysis, as transcription start sites have not been identified for the other eight genes. FOXO and E-box-binding sites were the most significantly overrepresented regulatory sequences upstream of the genes induced by PI 3-kinase inhibition in Rat-1 cells, consistent with previous results in T98G cells. 16 FOXO-binding sites were predicted upstream of about 70% of the upregulated genes (Po0.0001, FDR corrected) and E-box sites upstream of about 50% of the upregulated genes (Pp0.01, FDR corrected).
Computational predictions of FOXO and E-box binding sites were verified by ChIP assays. Binding of FOXO3a, and to a lesser extent FOXO1, was detected to predicted sites upstream of 10 genes that were induced in response to inhibition of PI 3-kinase, including Atrogin-1, Ccng2 and Txnip 18 ( Figure 3a) . These FOXO target genes included one gene whose induction was independent of p53 (Pdk4), as well as nine genes whose induction was inhibited by expression of dominant-negative p53 (Aspn, Atrogin-1,Ccng2, Gadd45A, Flcn, Hbp1, Hoxc5, Tp53inp1 and Txnip). Similarly, binding of MITF was detected to predicted E-box sites upstream of six of the genes induced by inhibition of PI 3-kinase (Figure 3b ). USF1 bound to the predicted E-box sequences upstream of the same six genes targeted by MITF, as well as to sequences upstream of Nr1d1 (Figure 3c) . As in the case of FOXO, the genes targeted by MITF and USF1 included both genes whose induction was inhibited (Atrogin-1, Ccng2, Gadd45A, Hbp1, Hoxc5 and Txnip) and whose induction was unaffected by dominant-negative p53 (Nr1d1).
ChIP assays also confirmed the binding of p53 to predicted sites upstream of all of the genes tested whose induction was inhibited by expression of dominant-negative p53 (Loc68916 and N5 were not included, as their upstream sequences could not be obtained for computational analysis) (Figure 4a ). The extent of binding of p53 to the predicted sequences upstream of these PI 3-kinase regulated genes was comparable to the binding of p53 upstream of Cdkn1a, which was included as a positive control.
There was substantial overlap in the genes targeted by FOXO, MITF, USF1 and p53 (Figure 4b ). In total, 14 of the 18 genes analyzed were targeted by either FOXO, MITF, USF1 or p53 transcription factors. All but five of these genes were targeted by members of at least two families of these transcription factors and six were targeted by all three. A total of 12 genes were targeted by p53, with nine of these genes also targeted by FOXO and six targeted by both FOXO and the E-box factors. It thus appears that p53 contributes to gene regulation downstream of PI 3-kinase signaling as part of an overlapping network of transcription factors that includes FOXO, MITF and USF1.
p53-regulated transcriptional network G Nayak et al GSK3 mediates activation of p53 in response to PI-3 kinase inhibition. We further explored the molecular mechanism underlying p53 regulation in response to PI-3 kinase inhibition. Intracellular levels of p53 are generally controlled by degradation mediated by the ubiquitin ligase MDM2. 24, 26 Previous studies have shown that MDM2 is stimulated by Akt phosphorylation, providing a potential link between p53 and PI 3-kinase signaling.
28,29 However, we did not observe any detectable increase in p53 levels after inhibition of PI-3 kinase, whereas the expected increase in p53 was readily apparent after treatment with low doses of actinomycin D ( Figure 5) . It thus appears that regulation of MDM2 and subsequent stabilization of p53 is not the major mechanism underlying p53 activation following inhibition of PI 3-kinase.
It has been recently shown that PI 3-kinase signaling can also regulate the activity of p53 as a result of phosphorylation of the acetyltransferase Tip60 by GSK3.
30 GSK3 phosphorylation on serine 86 activates Tip60, which then activates p53 via acetylation of lysine 120. 30 As inhibition of PI 3-kinase leads to activation of GSK3, we sought to determine whether GSK3 was responsible for activation of p53 by this mechanism.
As expected, inhibition of PI 3-kinase led to rapid dephosphorylation of both Akt and GSK3 (Figure 6a ), corresponding to activation of GSK3. Phosphorylation of Tip60 on serine 86 increased Bfourfold following inhibition of PI 3-kinase with either PI-103 or GDC-0941 (Figure 6b) . Likewise, inhibition of PI 3-kinase increased the acetylation of p53 lysine 120 by three-to-four-fold (Figure 6c ). Importantly, both Tip60 phosphorylation and p53 acetylation were blocked by treatment with the GSK3 inhibitor SB-21676, demonstrating the functional role of GSK3 in p53 activation. Inhibition of PI 3-kinase similarly resulted in GSK3-dependent phosphorylation of Tip60 (Figure 6d ) and acetylation of p53 (Figure 6e ) in PC12 rat pheochromocytoma cells.
These results indicated that activation of GSK3 following inhibition of PI 3-kinase led to activation of p53 via acetylation. We therefore sought to determine whether inhibition of GSK3 blocked transcriptional activation of p53 target genes following PI 3-kinase inhibition (Figure 7) . Treatment with the GSK3 inhibitor SB-216763 interfered with the induction of most of the p53-target genes, including Cdkn1a, confirming the role of GSK3 in p53 activation. However, the induction of some genes that were dependent on p53 (Flcn, Hoxc5, Loc688916 and Txnip) (Figure 2a) was not significantly reduced by inhibition of GSK3, consistent with the induction of these genes by other transcription factors or with the possibility that inhibition of PI-3 kinase can also activate p53 independently of GSK3 activity.
As GSK3 has a major role in activation of p53, as well as in activation of MITF and USF1, 18, 30 in response to inhibition of PI 3-kinase, we further investigated the role of GSK3 in apoptosis both in wild-type Rat-1 cells and in cells expressing dominant-negative p53. Inhibition of GSK3 significantly inhibited apoptosis induced by inhibition of PI 3-kinase in both wild-type Rat-1 cells and in the DN1 and DN2 cells expressing the dominant-negative p53 mutant (Figure 8) . These results indicate a role for GSK3 in both p53-dependent and p53-independent pathways, leading to apoptosis downstream of PI 3-kinase signaling, consistent with the role for GSK3 in gene regulation by p53, MITF and USF1.
Discussion
PI3-kinase/Akt signaling is required for the survival and growth of mammalian cells by coordinating the activities of a variety of downstream targets, including direct effectors of cell cycle progression and apoptosis, regulators of protein synthesis and autophagy, and proteins that control transcription and mRNA degradation. We have used global gene expression profiling to characterize the transcriptional program that is maintained by PI 3-kinase signaling in proliferating cells by investigating the changes in gene expression that result from inhibition of PI 3-kinase. 16, 18 These studies have indicated that inhibition of PI 3-kinase results in rapid induction of genes that inhibit cell cycle progression and/or induce apoptosis. The FOXO and E-box-binding transcription factors MITF and USF1 have been shown to have key roles in this transcriptional response, with FOXO being regulated by Akt and MITF and USF1 being activated via phosphorylation by GSK3. 18 The p53 transcription factor, which is a major regulator of cell proliferation and survival, can also be affected by PI 3-kinase signaling. p53 is typically activated in response to DNA damage, which results in stabilization of p53 and induction of target genes that induce cell cycle arrest and apoptosis.
24-27 PI 3-kinase/Akt signaling can impinge on the regulation of p53 via phosphorylation of MDM2, the ubiquitin ligase that targets p53 for proteasomal degradation. 28, 29 In this study, we therefore sought to determine whether p53 had a role in the cellular response to inhibition of PI 3-kinase signaling by comparing the effects of PI 3-kinase inhibition in Rat-1 cells (which express wild-type p53) to transfected cell clones stably-expressing a dominant-negative p53 mutant.
Expression of dominant-negative p53 inhibited but did not prevent apoptosis resulting from inhibition of PI 3-kinase. This is consistent with previous reports that p53 contributes to apoptosis induced by growth factor deprivation [42] [43] [44] and indicates that p53 is one of the effectors contributing to cell Table 1 . Data are presented as the percentage of input DNA bound and are the means of at least five independent experiments ± S.E. Myog was used as the negative control. *Indicates significant binding (Po0.05) following PI-103 treatment death when PI 3-kinase signaling is blocked. Our current results on the effects of p53 on transcriptional changes in response to PI 3-kinase inhibition were consistent with this partial effect on apoptosis. The expression of about half of the genes induced in response to inhibition of PI 3-kinase was reduced in cells expressing dominant-negative p53, although the effect of dominant-negative p53 on most of these genes was a partial rather than complete block to their induction. Consistent with the partial effect of p53 on gene induction, the genes induced by inhibition of PI 3-kinase in Rat-1 cells were 16, 18 Notably, many of the genes targeted by p53 were coregulated by FOXO and E-box transcription factors. Approximately 70% of the genes targeted by p53 were also targeted by FOXO, and nearly 50% of the genes targeted by p53 were also targeted by both FOXO and E-box-binding factors, indicating synergistic gene regulation by the transcription factors acting downstream of PI 3-kinase signaling. In agreement with this, FOXO transcription factors are known to cooperate with p53 and previous studies have identified cell cycle arrest and proapoptotic genes that are coregulated by p53 and FOXO transcription factors. 45 Activation of p53 in response to DNA damage and other forms of cell stress is generally mediated by inhibition of p53 degradation, leading to increased intracellular p53 levels. Although Akt can regulate p53 degradation via phosphorylation of MDM2, this did not appear to be a major mechanism of p53 regulation in response to PI 3-kinase inhibition, as intracellular levels of p53 did not significantly increase. Instead, activation of p53 was mediated primarily by a recently described pathway 30 in which GSK3 phosphorylates and activates the lysine acetyltransferase Tip60, which then activates p53 by acetylation. In this study, we confirmed this mechanism by demonstrating phosphorylation of Tip60 and acetylation of p53 in response to PI 3-kinase inhibition, both of which were blocked by inhibition of GSK3. Inhibition of GSK3 also blocked the induction of most p53-dependent genes in response to inhibition of PI 3-kinase, confirming the role of GSK3 in p53 activation. However, some p53-dependent genes were unaffected by inhibition of GSK3, suggesting that inhibition of PI 3-kinase may also lead to activation of p53 by other mechanisms, possibly as a result of phosphorylation of p53 by other stress-activated protein kinases, such as the c-Jun N-terminal kinase. 46 Inhibition of GSK3 also reduced, but did not completely block, apoptosis resulting from inhibition of PI 3-kinase in both wild-type Rat-1 cells and cells expressing dominant-negative p53. The reduction in apoptosis due to inhibition of GSK3 in both cell types suggests that p53 is one of several proapoptotic targets of GSK3, consistent with the identification of other GSK3 targets including MITF and USF1, 18, [47] [48] [49] Mcl-1 7 and eIF2B. 12 The finding that GSK3 reduced but did not eliminate apoptosis is also consistent with the direct effects of Akt on other proapoptotic effectors, including FOXO 19, 20 and Bad. 8, 9 p53 is thus one component of the network of transcription factors that contributes to changes in Finally, we note that the function of p53 downstream of PI 3-kinase signaling may be relevant to tumor therapy with drugs targeting PI 3-kinase. Mutations that activate PI 3-kinase signaling are frequently found in human cancers, and several inhibitors of PI 3-kinase are currently being evaluated in clinical trials.
1,2 Mutations of p53 are also extremely common in human cancer, 24, 26 and the role of p53 in inducing apoptosis downstream of PI 3-kinase signaling suggests that p53 mutations in tumors may confer partial resistance to PI 3-kinase inhibitors.
Materials and Methods
Cell culture and inhibitor treatments. Rat-1 fibroblasts were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum. PC12 rat pheochromocytoma cells were grown in DMEM supplemented with 10% fetal bovine serum and 5% horse serum. For inhibitor treatments, cells were plated at 10 6 cells per 100 mm dish and cultured for 48 h. Actively proliferating cells were treated with GDC-0941 (1 mM, Selleck Chemicals, Houston, TX, USA), PI-103 (5 mM, EMD Biosciences, San Diego, CA, USA), SB-216763 (5 mM, Biomol, Hamburg, Germany) or actinomycin D (10 nM, Sigma-Aldrich, St. Louis, MO, USA).
Isolation of Rat-1 cell clones expressing dominant-negative p53. Rat-1 cells were transfected with 1 mg of a plasmid expressing the dominant-negative V143A p53 cDNA under the control of a cytomegalovirus promoter and containing a geneticin (G418) resistance gene for selection. 33 3 Â 10 5 cells were plated in 35 mm plates 24 h before transfection. Transfections were performed with Lipofectamine (Invitrogen, Grand Island, NY, USA) according to the manufacturer's protocol. The following day, the standard medium was replaced with medium containing G418 (600 mg/ml). Individual G418-resistant colonies were isolated and expression of the exogenous mutant p53 was tested by immunoblot analysis. Cells were maintained in medium supplemented with 400 mg/ml G418.
Microarray analysis. Gene expression microarrays were performed with three independent RNA samples. Total RNA was extracted with TRIzol reagent (Invitrogen) and RNAs were further purified using a Qiagen (Valencia, CA, USA) RNeasy kit according to manufacturer's instructions. The quality of the RNA was determined using an Agilent (Santa Clara, CA, USA) bioanalyzer before analysis on Affymetrix (Santa Clara, CA, USA) Rat Gene 1.0ST microarrays. Microarray sample preparation/labeling, hybridization, scanning and subsequent data analysis were conducted by the Boston University Microarray Facility.
Real-time RT-PCR. Total RNA used for real-time RT-PCR was extracted using TRIzol extraction as per the manufacturer's protocol. Real-time RT-PCR was carried out as previously described. 41 Primer sequences can be found in Supplementary Table 2.
Immunoblotting. Cells were lysed in 2 Â Laemmli buffer. Proteins were separated by SDS-polyacrylamide gel electrophoresis through a 10% gel, transferred to polyvinylidene difluoride membrane, and immunoblotted overnight at 4 1C with antibodies to p53 (Cell Signaling Technology, Danvers, MA, USA, 9282), b-actin (Sigma-Aldrich), KAT5/Tip60 (Abcam, Cambridge, MA, USA, 23886), KAT5/Tip60 phospho S86 (Abcam, 73207), p53 acetyl K120 (Abcam, 8316), GSK3 (BD Biosciences, San Jose, CA, USA, g22320), GSK3 phospho S9 (Cell Signaling Technology, 9336), Akt (Cell Signaling Technology, 9272) and Akt phospho S473 (Cell Signaling Technology, 9271) as recommended by the manufacturers. Membranes were washed thrice in 1 Â Tris-buffered saline with 0.05% Tween 20, incubated in horseradish peroxidase linked to secondary antibody for 1 h at room temperature, washed thrice in Tris-buffered saline with 0.05% Tween 20 and then visualized using chemiluminescence. Densitometry was performed using Image J software (NIH).
Prediction of transcription factor binding sites. The prediction of transcription factor binding sites was carried out as described, 16, 41 utilizing the TRANSFAC 12.1 database and the MinSUM threshold in regions spanning 3-kb upstream of the transcription start sites. Overrepresented binding sites were determined by comparing the frequency of predicted sites in the set of upregulated genes to the frequencies in a background set of genes that were expressed in proliferating Rat-1 cells but not affected by inhibition of PI 3-kinase.
Chromatin immunoprecipitation. ChIPs were performed as previously described, 16 ,18 using 5 mg of the following antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA): anti-MITF (SC-25386), anti-USF1 (SC-229), anti-FOXO1 (SC-11350), anti-FOXO3a (SC-11351) and anti-p53 from Cell Signaling (9282). Immunoprecipitated DNA was quantified by real-time PCR using primers within 100 bp of predicted transcription factor binding sites. Primer sequences can be found in Supplementary Table 2 .
Apoptosis assay by DNA fragmentation. DNA fragmentation was assayed as previously described. 50 Briefly cells (5 Â 10 6 cells per 100 mm dish) were plated 24 h before treatment with PI-103. The cells were harvested, washed once with phosphate-buffered saline, and cytosolic nucleic acids were electrophoresed through a 1.5% agarose gel containing ethidium bromide. The gels were treated with 20 mg/ml RNase A for 4 h at 37 1C before visualization by UV transillumination.
TUNEL assay. Cells (1 Â 10 6 cells per 60 mm dish) were plated 24 h before treatment with PI-103, GDC-0941 or SB216763 and apoptotic cells were detected using a fluorescent-based FragEL DNA fragmentation kit (Calbiochem, San Diego, CA, USA, QIA39) according to the manufacturer's protocol. Following staining and washing, samples were passed into 5-ml polystyrene tubes containing cell strainer (352235, BD Biosciences) and analyzed by flow cytometry.
RNA interference and cell viability. Cells were plated at B2000 cells per well in 96-well plates and transfected with predesigned siRNAs against ATROGIN-1 (Ambion, Carlsbad, CA, USA, s139579), GADD45A (Ambion, s129010), NUPR1 (Ambion, s137294), TP53INP1 (Ambion, s128542), TXNIP (Ambion, s138748) or a nonspecific negative control (Ambion, 4390843) using Lipofectamine 2000 per the manufacturer's protocol. Cells were transfected with 10 nM siRNAs against ATROGIN-1 and GADD45A and 20 nM siRNAs against NUPR1, TP53INP1 and TXNIP, optimized for the individual gene targets. Cells were transfected for 48 h followed by PI 3-kinase inhibition for 24 h with 1 mM GDC-0941. The effect of target gene knockdown on cell viability was assayed using a standard MTT assay (Promega, Madison, WI, USA) per the manufacturer's protocol.
